As a result of this project, our facility instituted a new protocol using a reduced dose of alteplase to restore patency to non-HD CVADs” Plohal and Schiller (2017).
Central line-associated bloodstream infections (CLABSIs) are preventable through vigilant and thorough care.1 When CLABSIs occurred at a facility in Southwest Arizona, the root cause analysis discovered that declotting agents, such as alteplase, were not given routinely when nonhemodialysis (non-HD) central vascular access devices (CVADs) lacked blood return. A PICO question was developed that guided the review of literature and central line care standards of practice: In the adult patients with non-HD central lines, what medications are currently recommended to restore patency? As a result of this project, our facility instituted a new protocol using a reduced dose of alteplase to restore patency to non-HD CVADs.
ReTweet if useful… What is the most effective Alteplase dose to restore CVAD potency? https://ctt.ec/u6dRS+ @ivteam #ivteam
Plohal, A. and Schiller, K. (2017) Efficacy of Reducing Alteplase Dose to Restore Patency in Nonhemodialysis Central Vascular Access Devices. Journal of Infusion Nursing. 40(2), p.112–115.
Thank you to our partners for supporting IVTEAM